Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kimberly A Struble

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Current Opinion in HIV and AIDS|September 5, 2019
Considerations and challenges in developing novel long-acting antiretrovirals modalities for treatment and prevention of HIV-1 infection: a regulatory perspectiveMario R Sampson, Stephanie B Troy, Yodit Belew, et al.
AIDS (London, England)|April 5, 2019
Cobicistat-containing antiretroviral regimens are not recommended during pregnancy: viewpointSarita D Boyd, Mario R Sampson, Prabha Viswanathan, et al.
Journal of Clinical Pharmacology|February 28, 2008
Are literature references sufficient for dose recommendations? An FDA case study of efavirenz and rifampinJennifer L DiGiacinto, Kirk M Chan-Tack, Sarah M Robertson, et al.
AIDS (London, England)|November 14, 2008
HIV clinical trial design for antiretroviral development: moving forwardKirk M Chan-Tack, Kimberly A Struble, Nathalie Morgensztejn, et al.
Infection Control and Hospital Epidemiology|August 7, 2013
Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxisDavid T Kuhar, David K Henderson, Kimberly A Struble, et al.
International Journal of Clinical Pharmacology and Therapeutics|April 24, 2014
Why did the FDA approve efavirenz 800 mg when co-administered with rifampin?Jiang Liu, Kirk M Chan-Tack, Pravin Jadhav, et al.
AIDS Patient Care and Stds|June 28, 2012
Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008)Guoxing Greg Soon, Min Min, Kimberly A Struble, et al.
MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports|January 22, 2005
Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human ServicesDawn K Smith, Lisa A Grohskopf, Roberta J Black, et al.
Infection Control and Hospital Epidemiology|January 22, 2026
2025 US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Post-exposure Prophylaxis in Healthcare SettingsAaron D Kofman, Kimberly A Struble, Walid Heneine, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Current Opinion in HIV and AIDS|September 5, 2019
Considerations and challenges in developing novel long-acting antiretrovirals modalities for treatment and prevention of HIV-1 infection: a regulatory perspectiveMario R Sampson, Stephanie B Troy, Yodit Belew, et al.
AIDS (London, England)|April 5, 2019
Cobicistat-containing antiretroviral regimens are not recommended during pregnancy: viewpointSarita D Boyd, Mario R Sampson, Prabha Viswanathan, et al.
Journal of Clinical Pharmacology|February 28, 2008
Are literature references sufficient for dose recommendations? An FDA case study of efavirenz and rifampinJennifer L DiGiacinto, Kirk M Chan-Tack, Sarah M Robertson, et al.
AIDS (London, England)|November 14, 2008
HIV clinical trial design for antiretroviral development: moving forwardKirk M Chan-Tack, Kimberly A Struble, Nathalie Morgensztejn, et al.
Infection Control and Hospital Epidemiology|August 7, 2013
Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxisDavid T Kuhar, David K Henderson, Kimberly A Struble, et al.
International Journal of Clinical Pharmacology and Therapeutics|April 24, 2014
Why did the FDA approve efavirenz 800 mg when co-administered with rifampin?Jiang Liu, Kirk M Chan-Tack, Pravin Jadhav, et al.
AIDS Patient Care and Stds|June 28, 2012
Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008)Guoxing Greg Soon, Min Min, Kimberly A Struble, et al.
MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports|January 22, 2005
Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human ServicesDawn K Smith, Lisa A Grohskopf, Roberta J Black, et al.
Infection Control and Hospital Epidemiology|January 22, 2026
2025 US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Post-exposure Prophylaxis in Healthcare SettingsAaron D Kofman, Kimberly A Struble, Walid Heneine, et al.
Pageof 2